XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔

S
S

Sanofi

خبر

Reuters - 2 دن پہلے

Amgen-Sanofi patent case divides makers of antibody drugs

Amgen-Sanofi patent case divides makers of antibody drugs By Patrick Wingrove March 27 (Reuters) - Amgen Inc's AMGN.O battle with Sanofi SASY.PA and Regeneron REGN.O at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.
A
G
P
R
S
Reuters - 2 دن پہلے

U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents

UPDATE 3-U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents Recasts first paragraph, adds quotes from lawyers and Justice Thomas By John Kruzel and Andrew Chung WASHINGTON, March 27 (Reuters) - Amgen Inc AMGN.O sought to convince the U.S. Supreme Court on Monday to revive patents on its cholesterol-lowering drug Repatha, while rival Sanofi SA SASY.PA urged the justices not to stifle competition for therapies to address a common health risk.
A
R
S
Reuters - 2 دن پہلے

Pakistan defers decision on drug price rise as pharma firms struggle

UPDATE 1-Pakistan defers decision on drug price rise as pharma firms struggle Adds names of medicines in short supply, paragraph 11 By Ariba Shahid and Asif Shahzad KARACHI, Pakistan, March 27 (Reuters) - Pakistan on Monday deferred a decision on a request by pharmaceutical firms to raise the prices of more than 100 medicines, prolonging a stand-off with an industry struggling to stem losses from soaring inflation and a weakened currency.
S
S
Reuters - 2 دن پہلے

Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court

Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court By John Kruzel and Andrew Chung WASHINGTON, March 27 (Reuters) - The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc AMGN.O to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA SASY.PA called a "blatant attempt" to squeeze competitors out of the market.
A
R
S
Reuters - 3 دن پہلے

REUTERS NEWS SCHEDULE AT 10 p.m. GMT /6:00 a.m. SGT

REUTERS NEWS SCHEDULE AT 10 p.m. GMT /6:00 a.m. SGT Here are the top stories and upcoming coverage plans for Reuters text service as of 10 p.m. GMT /6:00 a.m. SGT. For a full schedule of news and events, go to our editorial calendar on Reuters Connect . TOP STORIES GLOBAL ISRAEL-POLITICS-JUDICIARY/ Netanyahu sacks defence minister who opposed judicial overhaul JERUSALEM (Reuters) - Israeli Prime Minister Benjamin Netanyahu on Sunday dismissed Defence Minister Yoav Gallant a day after he broke ra
A
F
R
S
T
L
Reuters - 5 دن پہلے

GSK loses bid to keep experts out of upcoming Zantac trial

UPDATE 3-GSK loses bid to keep experts out of upcoming Zantac trial New throughout; adds comment from plaintiffs, background By Maggie Fick and Brendan Pierson March 24 (Reuters) - A California judge on Thursday denied GSK Plc's GSK.L bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker facing lawsuits over the medicine in courts across the United States.
B
G
P
S
Reuters - 6 دن پہلے

U.S. STOCKS Manchester United, Verona Pharma, 89Bio

BUZZ-U.S. STOCKS ON THE MOVE-Manchester United, Verona Pharma, 89Bio Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq led the rally among Wall Street's main indexes as major rate-sensitive technology and growth stocks advanced after the Federal Reserve hinted it was close to pausing interest rate hikes amid turbulence in the banking sector.
A
A
B
C
F
I
J
N
N
R
S
T
L
R
U
U
D
F
G
M
Reuters - 6 دن پہلے

Pharma delivers, for others

BREAKINGVIEWS-Pharma delivers, for others The author is a Reuters Breakingviews columnist. The opinions expressed are their own. NEW YORK, March 23 (Reuters Breakingviews) - Regeneron Pharmaceuticals REGN.O and Sanofi SASY.PA have shown their blockbuster asthma and eczema drug, Dupixent, works unexpectedly well against chronic obstructive pulmonary disease (COPD).
G
R
S
Reuters - 6 دن پہلے

U.S. STOCKS Ollie, Commercial Metals, Copper Aluminum miners

BUZZ-U.S. STOCKS ON THE MOVE-Ollie, Commercial Metals, Copper Aluminum miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes climbed on Thursday as major rate-sensitive technology and growth stocks advanced after the Federal Reserve hinted it was close to pausing interest rate hikes amid turbulence in the banking sector.
A
A
B
I
J
N
N
R
S
T
L
R
U
U
D
F
G
M
Reuters - 6 دن پہلے

Health Rounds: Inexpensive diabetes drug cuts long COVID risk

Health Rounds: Inexpensive diabetes drug cuts long COVID risk Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here . By Nancy Lapid March 23 (Reuters) - Hello Health Rounds Readers! Briefly taking an inexpensive diabetes pill after the onset of COVID-19 can significantly reduce the risk of long COVID, a finding that one expert hailed as a "breakthrough." We also highlight the lates
R
S
Reuters - 6 دن پہلے

U.S. STOCKS U.S. banks, Regeneron, Gold miners

BUZZ-U.S. STOCKS ON THE MOVE-U.S. banks, Regeneron, Gold miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures climbed on Thursday, a day after the Federal Reserve hinted it was close to pausing its market-punishing interest rate hikes following the recent turmoil in the banking sector.
A
A
C
J
N
R
S
U
U
F
M
Reuters - 6 دن پہلے

Banks drag European shares down as c.banks join Fed in raising rates

UPDATE 2-Banks drag European shares down as c.banks join Fed in raising rates For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Banks down 2.4%, rate-sensitive tech up 2.2% Swiss, Norwegian central banks hike rates as expected BoE raises rates again, sees inflation shock fading Sanofi up on 'blow-out' smoker's lung drug data STOXX 600 slips 0.2% Updates details, prices; adds comment By Sruthi Shankar and Bansari Mayur Kamdar March 23 (Reut
C
R
S
U
S
E
F
U
G
Reuters - 1 ہفتے پہلے

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

UPDATE 5-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data Drug meets primary and all secondary goals in COPD trial Previous peak sales estimate of 13 bln euros was without COPD Drug could be first new COPD treatment in over a decade Adds Regeneron price, paragraph 5 By Ludwig Burger March 23 (Reuters) - Sanofi's SASY.PA asthma drug Dupixent met all targets in a trial to treat "smoker's lung", potentially adding billions to the French drugmaker's growth prospects, but also underscoring
A
R
S
Reuters - 1 ہفتے پہلے

Sanofi and Regeneron's Dupixent meets endpoints in clinical trial

Sanofi and Regeneron's Dupixent meets endpoints in clinical trial March 23 (Reuters) - Healthcare firms Sanofi SASY.PA and Regeneron REGN.O said their Dupixent product, which treats the skin disease atopic dermatitis, has met primary and all secondary endpoints in a trial to treat chronic obstructive pulmonary disease (COPD). Dupixent showed a 30% reduction in moderate or severe acute exacerbations of COPD, a respiratory disease that damages the lungs and causes progressive lung function decline
R
S
Reuters - 1 ہفتے پہلے

Sanofi Says Dupixent Shows Reduction In Exacerbations In Phase 3 Trial As A Potential Treatment For COPD

BRIEF-Sanofi Says Dupixent Shows Reduction In Exacerbations In Phase 3 Trial As A Potential Treatment For COPD March 23 (Reuters) - Sanofi SA SASY.PA : SANOFI-DUPIXENT SHOWS REDUCTION IN EXACERBATIONS IN PHASE 3 TRIAL AS A POTENTIAL TREATMENT FOR COPD SANOFI-PHASE 3 TRIAL OF DUPIXENT SHOWED SIGNIFICANT REDUCTION (30%) IN EXACERBATIONS COMPARED TO P
R
S
Reuters - 1 ہفتے پہلے

Sanofi-Aventis Canada - Health Canada Has Issued A Notice Of Compliance For Rezurock

BRIEF-Sanofi-Aventis Canada - Health Canada Has Issued A Notice Of Compliance For Rezurock March 21 (Reuters) - Sanofi SA SASY.PA : SANOFI-AVENTIS CANADA - HEALTH CANADA HAS ISSUED A NOTICE OF COMPLIANCE FOR REZUROCK Source text for Eikon: ID:nCNW61dZSa Further company coverage: SASY.PA
S
Reuters - 1 ہفتے پہلے

Sanofi/Regeneron say Dupixent skin treatment wins new regulatory approval in Europe

Sanofi/Regeneron say Dupixent skin treatment wins new regulatory approval in Europe PARIS, March 21 (Reuters) - Healthcare companies Sanofi SASY.PA and Regeneron REGN.O announced on Tuesday that their Dupixent product, which treats the skin disease atopic dermatitis, had won a new regulatory approval from the European Commission. The companies said the European Commission (EC) had approved Dupixent in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years
R
S
Reuters - 1 ہفتے پہلے

Sanofi: Dupixent® (Dupilumab) Receives An Approval By European Commission

BRIEF-Sanofi: Dupixent® (Dupilumab) Receives An Approval By European Commission March 21 (Reuters) - Sanofi SA SASY.PA : DUPIXENT® (DUPILUMAB) APPROVED BY EUROPEAN COMMISSION AS FIRST AND ONLY TARGETED MEDICINE FOR CHILDREN AS YOUNG AS SIX MONTHS OLD WITH SEVERE ATOPIC DERMATITIS APPROXIMATELY SEVEN TIMES AS MANY PATIENTS AGED 6 MONTHS TO 5 YEARS
S
Reuters - 1 ہفتے پہلے

Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

FOCUS-Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies By Jennifer Rigby LONDON, March 20 (Reuters) - Some of the world's leading makers of flu vaccines say they could make hundreds of millions of bird flu shots for humans within months if a new strain of avian influenza ever jumps across the species divide. One current outbreak of avian flu known as H5N1 clade 2.3.4.4b has killed record numbers of birds and infected mammals.
G
S
Reuters - 2 ہفتے پہلے

Sanofi Says Dupixent Late-Breaking Data At AAD Shows Significant Improvements In Signs & Symptoms Of Moderate-To-Severe Atopic Hand & Foot Dermatitis

BRIEF-Sanofi Says Dupixent Late-Breaking Data At AAD Shows Significant Improvements In Signs & Symptoms Of Moderate-To-Severe Atopic Hand & Foot Dermatitis March 18 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: DUPIXENT® (DUPILUMAB) LATE-BREAKING DATA AT AAD SHOW SIGNIFICANT IMPROVEMENTS IN SIGNS AND SYMPTOMS OF MODERATE-TO-SEVERE ATOPIC HAND
S

شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

ہم کوکیز کا استعمال آپکو ہماری ویب سائٹ پر بہتریں تجربہ دینے کیلیے کرتے ہیں۔ مزید پڑھیے یا اپنی کوکی سیٹنگ تبدیل کیجیے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔